RayzeBio Past Earnings Performance
Past criteria checks 0/6
RayzeBio's earnings have been declining at an average annual rate of -37.3%, while the Biotechs industry saw earnings growing at 15.3% annually.
Key information
-37.3%
Earnings growth rate
-8.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -11.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How RayzeBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 0 | -65 | 12 | 64 |
| 30 Jun 23 | 0 | -70 | 11 | 64 |
| 31 Mar 23 | 0 | -72 | 11 | 63 |
| 31 Dec 22 | 0 | -73 | 11 | 61 |
| 31 Dec 21 | 0 | -57 | 6 | 34 |
Quality Earnings: RYZB is currently unprofitable.
Growing Profit Margin: RYZB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RYZB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RYZB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RYZB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).
Return on Equity
High ROE: RYZB has a negative Return on Equity (-11.04%), as it is currently unprofitable.